Volume 58, Issue 5, November 2020

Coronavirus disease 2019 (COVID-19) is a new contagious disease, a public health emergency and a pandemic.

The worldwide spread of the novel coronavirus disease 2019 (COVID-19) pandemic, first identified in Wuhan, China, has created unprecedented challenges in the diagnosis and medical treatment of affected patients as well as in public health management.

Pulmonary embolism (PE) remains a significant complication of peripheral venous thrombosis with a reported incidence of 60–70 cases per 100 000 people [1].

Endovascular therapy for Stanford type B aortic dissection and/or intramural haematoma (ADB/IMHB) has been a topic of incessant debate for decades.

Repair of an extensive thoracic aortic aneurysm (ETAA), or ‘mega-aorta’ syndrome, represents a surgical challenge both technically and in postoperative management.

Acute type A aortic dissection (ATAAD) is a life-threatening disease that develops suddenly and requires emergency surgery.

Mitral and tricuspid valve repair is always the first option in infants and small children, with improving outcomes [1–3].

Median sternotomy is considered as the standard approach for the treatment of congenital heart defects (CHDs), especially for complex abnormalities.

Prolonged air leak following lung injury results in decreased quality of life and extended hospital stay.

Since the outbreak of the novel coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in Wuhan, China [1], over 4.9 million cases have been diagnosed around the world [2].

Acute type A aortic dissection (ATAAD) is a life-threatening condition for which emergent surgical treatment is essential [1].

Cerebral injury is a feared complication in cardiac surgery.